Comparative Pharmacology
Head-to-head clinical analysis: FLUNISOLIDE versus HEXADROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUNISOLIDE versus HEXADROL.
FLUNISOLIDE vs HEXADROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory action; inhibits release of inflammatory mediators (e.g., histamine, leukotrienes), reduces eosinophil migration, and stabilizes mast cells. Suppresses cytokine production and adhesion molecule expression.
Synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to regulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
50 mcg per nostril twice daily (total daily dose 200 mcg), via nasal spray.
Adult: 0.75-9 mg/day orally in divided doses every 6-12 hours; IV/IM: initial 0.5-9 mg/day in divided doses every 6-12 hours.
None Documented
None Documented
Clinical Note
moderateFlunisolide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Gatifloxacin."
Clinical Note
moderateFlunisolide + Rosoxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Rosoxacin."
Clinical Note
moderateFlunisolide + Levofloxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Levofloxacin."
Clinical Note
moderateFlunisolide + Trovafloxacin
Terminal elimination half-life is 1.8 hours (range 1.3–2.5 h) after intravenous administration; clinically, endogenous suppression persists up to 24 h post-inhalation.
Terminal elimination half-life: 36-54 hours; prolonged in hepatic impairment (up to 72 hours) due to reduced clearance.
Renal (50%) as metabolites, fecal (40%) as metabolites via bile, <5% unchanged in urine.
Primarily renal: ~65-80% as unchanged drug and metabolites via glomerular filtration, with tubular reabsorption; minor biliary/fecal (5-10%).
Category C
Category C
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Trovafloxacin."